Allen Geltzer, MD
Internal Medicine · Bellevue, WANPI 1497775928
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$244
- Johnson & Johnson$180
- Pfizer$150
- Merck$114
- AstraZeneca$80
- Boehringer Ingelheim$74
- plus $412 from 14 others
Across 7 payments — averaging $1785.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$9K
- Novo Nordisk AS$4K
What the payments were for
- Food & beverage$1,254100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $244 |
| Johnson & Johnson | 8 | $180 |
| Pfizer | 10 | $150 |
| Merck | 8 | $114 |
| AstraZeneca | 5 | $80 |
| Boehringer Ingelheim | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Novartis | 3 | $58 |
| Astellas Pharma US Inc | 2 | $45 |
| GSK | 2 | $32 |
| Amarin Pharma, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $17 |
| Boston Scientific | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,254 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $154,050 |
| XareltoRivaroxaban | 36 | $44,935 |
| JanuviaSitagliptin Phosphate | 20 | $28,456 |
| Atorvastatin Calcium | 545 | $5,706 |
| PremarinEstrogens, Conjugated | 12 | $5,474 |
| Irbesartan | 254 | $4,209 |
| Tamsulosin Hcl | 208 | $4,036 |
| Ezetimibe | 101 | $3,180 |
| Esomeprazole Magnesium | 21 | $2,860 |
| Metoprolol Succinate | 223 | $2,824 |
| Omeprazole | 152 | $2,609 |
| Lisinopril | 227 | $2,390 |
| Rosuvastatin Calcium | 210 | $2,324 |
| Levothyroxine Sodium | 235 | $2,299 |
| Losartan Potassium | 232 | $2,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $150 | $159,524113 claims |
| Johnson & JohnsonXarelto | $180 | $44,93536 claims |
| MerckJanuvia | $114 | $28,45620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Bellevue
- Lawrence LoebBellevue$784K
- Gary SchusterBellevue$16K
- Tatyana KutsyBellevue$13K
- Peter ShalitSeattle$1M
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.